Clinical Trials

Toll-Free: 866.320.4573

Call Us Toll Free:

866.223.2273 x1234

Study Using IMC-A12 or IMC-1121B Plus Mitoxantrone and Prednisone in Metastatic Androgen-Independent Prostate Cancer, Following Disease Progression on Docetaxel-Based Chemotherapy

Study:

A Phase 2, Multicenter, Randomized Study of IMC-A12 or IMC-1121B Plus Mitoxantrone and Prednisone in Metastatic Androgen-Independent Prostate Cancer (AIPC) Following Disease Progression on Docetaxel-Based Chemotherapy

Rationale:

n/a

Purpose:

The purpose of this study is to determine whether IMC-A12 or IMC-1121B with Mitoxantrone and Prednisone is effective in the treatment of metastatic androgen- independent prostate cancer.

Study Status: Recruiting

Recruiting:
n/a

Condition Intervention Phase
Metastatic Androgen-Independent Prostate Cancer Drug: IMC-1121B and IMC-A12 Phase 2

Verified by ImClone Systems September, 2008

Sponsored by: ImClone Systems
Information provided by: ImClone Systems
ClinicalTrials.gov identifier: NCT00683475

Study Type: Interventional

Study Design: Treatment, Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study

Cleveland Clinic
Cleveland, Ohio 44195
United States

n/a

This information is abridged to display results relevant only to Cleveland Clinic. To see complete record visit ClinicalTrials.gov
  Information obtained from ClinicalTrials.gov on
Link to the current ClinicalTrials.gov record.